April 3, 2017 / 12:15 PM / 5 months ago

BRIEF-Sunesis Pharmaceuticals reports presentation of preclinical study of btk inhibitor sns-062

April 3 (Reuters) - Sunesis Pharmaceuticals Inc:

* Sunesis Pharmaceuticals announces presentation of the ohio state university-sponsored preclinical study of btk inhibitor sns-062 at aacr annual meeting

* Sunesis Pharmaceuticals - study demonstrated that, unlike ibrutinib, sns-062 inhibition of btk signaling is unaffected by presence of c481s mutation

* Sunesis Pharmac- with active ind, remain on track to dose first patient in planned phase 1b/2 study in patients with advanced b-cell malignancies this quarter Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below